// App-Quantinova.ai

POS0668 (2021) : REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

Researchers

Presenter

  • B. Gilbert

Principal Investigators

  • D. Courvoisier

  • D. Mongin

  • K. Lauper

  • C. Perrier

  • R. Muller

  • A. Finckh

Medical Centers

  • Geneva University Hospitals, Division of Cardiology, Geneva, Switzerland

  • Univ of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom

  • Eli Lilly SA (Suisse), Medical Department, Vernier, Switzerland

  • Kantonsspital Aarau, Medical University Department, Aarau, Switzerland

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Baricitinib

  • Rituximab

  • BARI

Outcome

  • N/A


Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A